Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.

Neurochemical Research
Chao LiWeidong Le

Abstract

Pramipexole (PPX), a dopamine (DA) receptor D3 preferring agonist, has been used as monotherapy or adjunct therapy to treat Parkinson's disease (PD) for many years. Several in vitro and in vivo studies in neurotoxin-induced DA neuron injury models have reported that PPX may possess neuroprotective properties. The present study is to evaluate the neuroprotection of PPX in a sustained DA neuron degeneration model of PD induced by ubiquitin-proteasome system (UPS) impairment. Adult C57BL/6 mice were treated with PPX (low dose 0.1 mg/kg or high dose 0.5 mg/kg, i.p, twice a day) started 7 days before, and continued after microinjection of proteasome inhibitor lactacystin in the medial forebrain bundle for a total 4 weeks. Animal behavior observation, and pathological and biochemical assays were conducted to determine the neuroprotective effects of PPX. We report here that PPX treatment significantly improves rotarod performance, attenuates DA neuron loss and striatal DA reduction, and alleviates proteasomal inhibition and microglial activation in the substantia nigra of lactacystin-lesioned mice. PPX can increase the levels of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor and induce an activation ...Continue Reading

References

Nov 14, 2000·Journal of Chemical Neuroanatomy·J R Glaser, E M Glaser
Dec 2, 2000·Science·D J Klionsky, S D Emr
Dec 2, 2000·Nature Neuroscience·R BetarbetJ T Greenamyre
Jun 23, 2001·Drugs & Aging·W D Le, J Jankovic
Dec 14, 2002·Lancet·C E Clarke, M Guttman
Jan 19, 2005·Journal of Molecular Neuroscience : MN·Heather Snyder, Benjamin Wolozin
Jun 14, 2005·Biochemical and Biophysical Research Communications·Xiong ZhangWeidong Le
Jul 19, 2005·Annual Review of Neuroscience·Darren J MooreTed M Dawson
Oct 7, 2005·Neurobiology of Aging·Kevin St P McNaught, C Warren Olanow
Nov 26, 2005·The European Journal of Neuroscience·Fang DuWeidong Le
Oct 5, 2006·Journal of Neural Transmission. Supplementum·G U HöglingerE C Hirsch
Dec 19, 2006·Current Opinion in Pharmacology·Jeffrey N Joyce, Mark J Millan
Mar 17, 2007·Lancet Neurology·Marta Martinez-Vicente, Ana Maria Cuervo
Aug 11, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Wen ZhuWeidong Le
Aug 15, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Lynn BedfordR John Mayer
Nov 15, 2008·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry· Weidong LeJoseph Jankovic
May 8, 2009·Biochimica Et Biophysica Acta·Casey Cook, Leonard Petrucelli
Oct 22, 2009·Current Medical Research and Opinion·Stefan Albrecht, Erich Buerger
Oct 23, 2009·Annals of Neurology·C Warren Olanow, Jeffrey H Kordower

❮ Previous
Next ❯

Citations

May 18, 2013·Journal of Molecular Neuroscience : MN·Kai-Yin ChauAnthony Henry V Schapira
Aug 5, 2011·Drugs & Aging·Claire Henchcliffe, W Lawrence Severt
Dec 8, 2010·Biomarkers in Medicine·Antonio Lucio TeixeiraArthur Kummer
Dec 10, 2013·Expert Opinion on Investigational Drugs·Fabio Blandini, Marie-Therese Armentero
Jul 24, 2010·Journal of Neurochemistry·Wenjie XieWeidong Le
Dec 30, 2014·Ageing Research Reviews·Niki ChondrogianniEfstathios S Gonos
Nov 2, 2016·Journal of Parkinson's Disease·Eduard BenteaAnn Massie
May 23, 2018·International Journal of Molecular Sciences·Dongmei WangXin Zhang
Feb 24, 2019·Toxicological Sciences : an Official Journal of the Society of Toxicology·Chunjuan SongAnumantha G Kanthasamy
Jul 5, 2011·Expert Review of Neurotherapeutics·Santiago Perez-LloretOlivier Rascol
Nov 7, 2018·Molecular Neurobiology·Khosro JamebozorgiAmirhossein Sahebkar
Jan 24, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Diego Luis-RaveloTomas Gonzalez-Hernandez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Parkinson's Disease & Autophagy (MDS)

Autophagy leads to degradation of damaged proteins and organelles by the lysosome. Impaired autophagy has been implicated in several diseases. Here is the role of autophagy in Parkinson’s disease.

Parkinson's Disease & Autophagy

Autophagy leads to degradation of damaged proteins and organelles by the lysosome. Impaired autophagy has been implicated in several diseases. Here is the role of autophagy in Parkinson’s disease.

Autophagy & Disease

Autophagy is an important cellular process for normal physiology and both elevated and decreased levels of autophagy are associated with disease. Here is the latest research.